AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06069245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules
Study NCT05611879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
Study NCT05611879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)
Description: Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
Study NCT05611879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
Study NCT06141590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UI068
Description: Test
Study NCT06141590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UIC202205, UIC202206
Description: Reference
Study NCT06479798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)
Description: Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
Study NCT04931862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide (ASO)
Study NCT04931862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Artificial cerebrospinal fluid (aCSF)
Study NCT06142045 — intervention group
Intervention type: DEVICE
Intervention: RespirACT RA-MR System
Description: RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
Study NCT04813133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
Study NCT05586061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin
Description: Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
Study NCT05586061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
Study NCT05586061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
Study NCT06560164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell transfusion
Description: When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.
Study NCT06560138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: SHR-4602 will be administered through IV infusion.
Study NCT05899595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises.
Study NCT05899595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise protocol
Description: Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises.
Study NCT05763576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7565020
Description: RO7565020 will be administered by subcutaneous injection or intravenous infusion.
Study NCT05763576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered by subcutaneous injection or intravenous infusion.
Study NCT05763576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NUC) treatment
Description: NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
Study NCT05867836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA vs. MMS during pregnancy
Description: Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
Study NCT05867836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA vs. MMS during pregnancy
Description: Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
Study NCT06582043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study NCT06435169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.
Description: The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
Study NCT06085989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant directed singing
Description: In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
Study NCT06085989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
Study NCT06455683 — intervention group
Intervention type: PROCEDURE
Intervention: Glaucoma Surgery
Description: One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment
Study NCT06423339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Genicular nerve block
Description: Ultrasound guided genicular nerve block
Study NCT06423339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
Description: Ultrasound guided Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
Study NCT06423339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: Ultrasound guided sub-sartorial Adductor canal block
Study NCT04810390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Ophthalmic solution 0.6%
Study NCT04810390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic solution
Study NCT05937269 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence lymphatic imaging
Description: All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
Study NCT05937269 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Near-infrared fluorescence lymphatic imaging
Description: All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
Study NCT06423339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Pupivacaine 0.5% in 20 ml vial
Study NCT05196815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
Study NCT05196815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheters
Description: During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
Study NCT05196815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft study wire
Description: Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
Study NCT05196815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-ray
Description: Participants will have chests x-ray when the soft study wire is inserted.
Study NCT05196815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
Study NCT05621187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pamira ICD lead family
Description: Implantation, measurements and follow-up schedule
Study NCT05992259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
Study NCT05992259 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
Study NCT06474091 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT05937269 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared fluorescence lymphatic imaging
Description: All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
Study NCT05937269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: advanced pneumatic compression therapy
Description: The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
Study NCT04990388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Small-quantity lipid-based nutrient supplement
Description: Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement
Description: Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provitamin A biofortified maize
Description: Provitamin A Maize Meal is orange maize-meal processed from provitamin A-rich orange maize. PVA maize meal will be sourced from International Maize and Wheat Improvement Centre (CIMMYT). Children in the intervention arm will consume 13g - 128g of pro-vitamin A (PVA) maize meal, with added powders. Each family will receive a monthly ration of 5kg PVA maize and this ration takes into consideration of household sharing. Families with children in the IYCF arm will receive white maize meal.
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUA-45 biofortified sugar beans
Description: NUA 45 bean powder is ground from roasted iron and zinc-rich biofortified sugar beans. NUA 45 bean powder will be sourced from Sky Brands Ltd Company. Children will consume a daily dose of 5g - 15g of NUA 45 bean powder added to complementary foods.
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera
Description: Moringa oleifera is an edible plant abundant in dry tropic regions including Zimbabwe. It is known to be rich in micronutrients and has been widely used in Zimbabwe and around the world both as a food and a herb. Moringa oleifera leaf powder, is a dried and ground powder produced from Moringa oleifera leaves using traditional methods. It has been widely used to fortify complementary foods in the African region with the aim of improving micronutrient status. Moringa oleifera leaf powder will be sourced from Lemex Products Company. Children will receive a daily dose of 5g - 15g of Moringa leaf powder added to complementary foods.
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: Egg Powder is hydrolysed non-genetically modified organism (GMO), fine and unflavoured whole egg powder. It is processed with no additives, preservatives, lecithin, added sugar, soy or monosodium glutamate. Egg powder will be sourced from France (A \& D Food Ingredients - distributor in South Africa). Children in the IYCF-plus arm will receive a daily dose of 14g egg powder. A 15% extra amount of egg powder will be provided to families taking into consideration of household sharing. Egg powder will be provided in sealed plastic jars similar to that of peanut butter and households will receive promotion messages to store the powder in a cool, dry place and avoiding contact with water or moisture during use.
Study NCT04874688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White maize meal
Description: Commercial white maize meal will be provided monthly. Infants age 6-8 months will receive 45g (3 tablespoons) daily; infants aged 9-12 months will receive 71g (4.5 tablespoons) daily.
Study NCT06000098 — intervention group
Intervention type: OTHER
Intervention: Restrictive fluid therapy
Description: 0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
Study NCT06347536 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Supported rescue pack
Description: 1) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
Study NCT05131399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase A1
Description: Plastic standard ankle foot orthosis
Study NCT05131399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase B1
Description: carbon medical device ankle foot orthosis
Study NCT05131399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase A2
Description: Plastic standard ankle foot orthosis
Study NCT05131399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase B2
Description: carbon medical device ankle foot orthosis
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous (SC) Injection
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Tablet
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Injection
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Injection
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV Injection
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV Infusion
Study NCT06191744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV Infusion
Study NCT05728463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
Study NCT05728463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
Study NCT04949126 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: questionnaires of precarity, dental anxiety, self medication, pain
Study NCT04915989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-19N
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
Study NCT05143307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBT-101
Description: Long term follow up of participants who received EBT-101